Aggressive dose de-escalation of radiotherapy provides similar efficacy and superior safety profile in patients with human papilloma virus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC), according to a recent study presented at the 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO).
Hypofractionated radiotherapy (HFRT) is equally effective and safe compared with conventional fractionated RT (CFRT) in Chinese breast cancer patients who have undergone mastectomy, according to a phase III study presented at the American Society for Radiation Oncology (ASTRO) 2017 Annual Meeting. [ASTRO 2017, abstract 5]
Use of consolidative stereotactic ablative radiotherapy (SAbR) prior to maintenance chemotherapy improves progression-free survival (PFS) by more than 6 months in patients with non-small-cell lung cancer (NSCLC) who have limited metastases, a recent phase II study has shown. [ASTRO 2017, abstract LBA3; JAMA Oncol 2017, doi: 10.1001/jamaoncol.2017.3501]
Combination therapy with the CTLA-4 blocker, ipilimumab, and stereotactic ablative radiation therapy (SABR) is effective in cancers with metastatic lung and liver lesions, according to results presented at the 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO).
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Oncology - Malaysia digital copy today!
An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.
Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.
At a median follow-up of 22.9 months, atezolizumab plus carboplatin and etoposide (CP/ET), given as a first-line treatment, continued to demonstrate an improvement in overall survival (OS) vs placebo plus CP/ET in patients with extensive-stage small-cell lung cancer (ES-SCLC), according to updated results of the IMpower133 trial presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.